| Literature DB >> 11939266 |
Masahiro Masuya1, Naoyuki Katayama, Koichi Inagaki, Hiroshi Miwa, Natsuki Hoshino, Hiroyuki Miyashita, Hirohito Suzuki, Hiroto Araki, Hidetsugu Mitani, Kazuhiro Nishii, Shin-ichi Kageyama, Nobuyuki Minami, Hiroshi Shiku.
Abstract
We describe a 55-year-old Japanese woman with therapy-related myelodysplastic syndrome (t-MDS) with 2 independent clones, t(1;2)(p36;p21) and t(11;12)(pl5;ql3). She was diagnosed with acute myeloid leukemia (AML) with cytological features of the bone marrow and peripheral blood. Cytogenetic evaluation revealed a 46,XX karyotype. She received chemotherapy and achieved complete remission (CR). Despite maintenance chemotherapy, she suffered a relapse. Chromosomal analysis showed t(1;2)(p36;p21) in 2 of 20 metaphases. At second CR, this clone transiently disappeared. Nine months later, t(1;2) (p36;p21) was detected again in 3 of 20 metaphases while the patient remained in CR. Six months later, bone marrow examination disclosed trilineage dysplasia without an excess of blasts, suggesting MDS. t(1;2)(p36;p21) was observed in 16 of 20 metaphases. The clinical course and serial cytogenetic findings were diagnostic of t-MDS. The duration of t-MDS was 6 years. During this period, persistent t(1;2)(p36;p21) and transient t(11;12)(p15;q13) were found. When t-MDS evolved toAML, cytogenetic evaluation revealed 46,XX,t(1;2)(p36;p21),del(7)(q22),add(19)(p13).Entities:
Mesh:
Substances:
Year: 2002 PMID: 11939266 DOI: 10.1007/BF02982025
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490